Adjuvanted Influenza Vaccines Versus Other Influenza Vaccines in Adults Aged ≥60 Years: A Systematic Review and Meta-Analysis of Relative Effectiveness for Preventing Influenza-Related Hospitalization
The exploratory synthesis did not show a clear difference between MF59-adjuvanted and high-dose vaccines, but sensitivity to outcome selection, heterogeneity estimation and potentially overlapping populations limits interpretation.